SirnaMed Therapeutics
Sewickley, US · Founded 2023 · Delaware corporation
Founders & leadership
Board
SM
Stanley MarksBoard director
Reported raises · per SEC filings
Form D private placements$1.3M disclosed across 1 round · 2024
▶$1.3MraisedJul 2024 · 9 investors · PharmaceuticalsRule 506(b)
▶$1.3MraisedJul 2024 · 9 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Phong TranExecutive Officer
- Stanley MarksDirector
- Jing-Zhou HouExecutive Officer, Director, Promoter
- Song LiExecutive Officer, Director, Promoter
- Offering amount
- $1.5M
- Amount sold
- $1.3M
- Minimum investment
- $50K
- Proceeds to insiders
- $165K
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- How much funding has SirnaMed Therapeutics raised?
- SirnaMed Therapeutics has disclosed $1.3M raised across 1 round.
- Where is SirnaMed Therapeutics headquartered?
- SirnaMed Therapeutics is headquartered in Sewickley, US.